Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1952 2
1953 2
1954 1
1955 3
1962 1
1963 1
1967 1
1972 1
1973 1
1975 2
1976 1
1977 1
1978 1
1983 1
1984 1
1989 1
1990 1
1993 2
1994 8
1995 5
1996 1
1997 2
1998 3
2000 3
2001 9
2002 10
2003 8
2004 7
2005 8
2006 16
2007 10
2008 14
2009 12
2010 15
2011 14
2012 26
2013 27
2014 33
2015 32
2016 26
2017 28
2018 22
2019 29
2020 26
2021 29
2022 21
2023 24
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

462 results

Results by year

Filters applied: . Clear all
Page 1
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. Among authors: melichar b. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
The Role of Adjuvant Radiotherapy in the Treatment of Breast Cancer.
Kolářová I, Melichar B, Sirák I, Vaňásek J, Petera J, Horáčková K, Pohanková D, Ďatelinka F, Šinkorová Z, Vošmik M. Kolářová I, et al. Among authors: melichar b. Curr Oncol. 2024 Feb 24;31(3):1207-1220. doi: 10.3390/curroncol31030090. Curr Oncol. 2024. PMID: 38534923 Free PMC article. Review.
The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting.
Kopecký J, Pásek M, Lakomý R, Melichar B, Mrazová I, Kubeček O, Arenbergerová M, Lemstrová R, Švancarová A, Tretera V, Hlodáková A, Žváčková K. Kopecký J, et al. Among authors: melichar b. Cancer Med. 2024 Mar;13(5):e6982. doi: 10.1002/cam4.6982. Cancer Med. 2024. PMID: 38491825 Free PMC article.
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators. Powles T, et al. N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117. N Engl J Med. 2024. PMID: 38446675 Clinical Trial.
Association of the combined parameters including the frequency of primary cilia, PD-L1, Smoothened protein, membranous β-catenin and cytoplasmic β-catenin expression with the outcome of patients with clear cell renal cell carcinoma.
Rozsypalova A, Rosova B, Filipova A, Nikolov DH, Chloupkova R, Richter I, Zachoval R, Matej R, Melichar B, Buchler T, Dvorak J. Rozsypalova A, et al. Among authors: melichar b. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2024 Feb 29. doi: 10.5507/bp.2024.005. Online ahead of print. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2024. PMID: 38420990
462 results